# A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

> **NCT02462473** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 9 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Olanzapine
- **DRUG:** Paliperidone
- **DRUG:** Quetiapine
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT02462473
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462473, "A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02462473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*